NCT03635567 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03635567
Title	Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Recruitment	Completed
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme Corp.
Indications	cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous carcinoma
Therapies	Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUS \| ARG

No variant requirements are available.